skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Zalutumumab (Code C64620)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Zalutumumab

Definition: A fully human IgG1 monoclonal antibody against epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR is a cell surface receptor tyrosine kinase, overexpressed on many cancer cells. Zalutumumab selectively binds to and blocks binding of EGF and transforming growth factor-alpha (TGF-a) to the EGFR receptor, thereby interfering with cellular signaling, leading to cell growth inhibition and apoptosis in tumor cells. In addition, zalutumumab also triggers cell lysis mediated through antibody dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells.

Display Name: Zalutumumab

Label: Zalutumumab

NCI Thesaurus Code: C64620 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831978  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HuMax-EGFr, 2F8

External Source Codes: 
CAS Registry Number 667901-13-5 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 518289
PDQ Open Trial Search ID 518289 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831978

Other Properties:
     Name Value (qualifiers indented underneath)
code C64620
Contributing_Source CTRP
Legacy_Concept_Name Zalutumumab
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom